Literature DB >> 29413518

Unique Effects of Clozapine: A Pharmacological Perspective.

Jibran Y Khokhar1, Angela M Henricks1, Emily D K Sullivan1, Alan I Green2.   

Abstract

Schizophrenia is a heterogenous and severe neuropsychiatric disorder that affects nearly 1% of the population worldwide. Antipsychotic drugs are the mainstay of treatment, but not all patients with schizophrenia respond to treatment with these agents. Clozapine, the first atypical antipsychotic, is a highly effective medication for patients with schizophrenia who do not respond to other antipsychotics. Although clozapine tends not to produce extrapyramidal symptoms, other side effects of the drug (e.g., agranulocytosis, myocarditis, seizures) limit its widespread use. This chapter reviews clozapine's unique clinical effects and unusual pharmacological profile. In addition to its effects in treatment-resistant schizophrenia, clozapine has been shown to decrease suicidality, which occurs at an increased rate in patients with schizophrenia. Still preliminary, but consistent data, also suggest that clozapine limits substance use in these patients, an important effect since substance use disorders are common in patients with schizophrenia and are associated with a poor outcome, including an increased risk for suicide and poor response to treatment. We have suggested, from animal studies, that clozapine's apparent ability to limit substance use may occur through its actions as a weak dopamine D2 receptor antagonist, a potent norepinephrine α-2 receptor antagonist and a norepinephrine reuptake inhibitor. Using animal models, we have built combinations of agents toward creation of safer clozapine-like drugs to reduce substance use in these patients. Future research into the mechanisms of action of clozapine toward the development of safe clozapine-like agents is of great public health importance.
© 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clozapine; Schizophrenia; Substance abuse; Suicide

Mesh:

Substances:

Year:  2018        PMID: 29413518     DOI: 10.1016/bs.apha.2017.09.009

Source DB:  PubMed          Journal:  Adv Pharmacol        ISSN: 1054-3589


  25 in total

1.  Clozapine Induced Hypertension and its Association with Autonomic Dysfunction.

Authors:  M B Deepak; Kalra Deeksha; Rajhans Pallavi; Choudhary Hemant; Bajaj Nidhisha; Deep Raman
Journal:  Psychopharmacol Bull       Date:  2021-11-03

2.  Insomnia and suicide as reported adverse effects of second-generation antipsychotics and mood stabilizers.

Authors:  Brian J Miller; William V McCall
Journal:  J Clin Sleep Med       Date:  2022-02-01       Impact factor: 4.062

3.  Tardive Dyskinesia: Spotlight on Current Approaches to Treatment.

Authors:  Sarah M Debrey; David R Goldsmith
Journal:  Focus (Am Psychiatr Publ)       Date:  2021-01-25

4.  A Case Report of Baclofen- and Clozapine-Induced Dyskinesia: A Movement Disorder.

Authors:  Maisha Maliha; Zinath Roksana; Priyata Dutta; Md Y Mamoon; Mohammed Q Islam
Journal:  Cureus       Date:  2022-05-17

5.  Impact cérébral structurel et fonctionnel de la Clozapine chez les patients souffrant de schizophrénie : revue systématique des études longitudinales en neuroimagerie.

Authors:  Anaïs Vandevelde; Lucie Métivier; Sonia Dollfus
Journal:  Can J Psychiatry       Date:  2020-11-02       Impact factor: 4.356

6.  Long-Term Real-World Effectiveness of Pharmacotherapies for Schizoaffective Disorder.

Authors:  Jonne Lintunen; Heidi Taipale; Antti Tanskanen; Ellenor Mittendorfer-Rutz; Jari Tiihonen; Markku Lähteenvuo
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 9.306

Review 7.  Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors.

Authors:  Domenico De Berardis; Michele Fornaro; Alessandro Valchera; Marilde Cavuto; Giampaolo Perna; Marco Di Nicola; Gianluca Serafini; Alessandro Carano; Maurizio Pompili; Federica Vellante; Laura Orsolini; Annastasia Fiengo; Antonio Ventriglio; Kim Yong-Ku; Giovanni Martinotti; Massimo Di Giannantonio; Carmine Tomasetti
Journal:  Int J Mol Sci       Date:  2018-09-23       Impact factor: 5.923

8.  Dopaminergic control of ADAMTS2 expression through cAMP/CREB and ERK: molecular effects of antipsychotics.

Authors:  Fulgencio Ruso-Julve; Ana Pombero; Fuencisla Pilar-Cuéllar; Nuria García-Díaz; Raquel Garcia-Lopez; María Juncal-Ruiz; Elena Castro; Álvaro Díaz; Javier Vazquez-Bourgón; Agustín García-Blanco; Emilio Garro-Martinez; Helena Pisonero; Alicia Estirado; Rosa Ayesa-Arriola; Juan López-Giménez; Federico Mayor; Elsa Valdizán; Javier Meana; Javier Gonzalez-Maeso; Salvador Martínez; José Pedro Vaqué; Benedicto Crespo-Facorro
Journal:  Transl Psychiatry       Date:  2019-11-18       Impact factor: 6.222

Review 9.  Alcohol Use Disorder and Schizophrenia or Schizoaffective Disorder.

Authors:  Luke Archibald; Mary F Brunette; Diana J Wallin; Alan I Green
Journal:  Alcohol Res       Date:  2019-12-20

10.  Clozapine Management in Schizophrenia Inpatients: A 5-Year Prospective Observational Study of Its Safety and Tolerability Profile.

Authors:  Renato de Filippis; Raffaele Gaetano; Georgios Schoretsanitis; Giuseppe Verde; Cesare Anthony Oliveti; John M Kane; Cristina Segura-Garcia; Pasquale De Fazio
Journal:  Neuropsychiatr Dis Treat       Date:  2021-07-01       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.